RESUMO
Mutations in OPA1 are responsible of 32-89% cases of Autosomal Dominant Optic Atrophy (ADOA). OPA1 ADOA usually presents in childhood with bilateral, progressive visual loss due to retinal ganglion cells neurodegeneration, but environmental factors are supposed to influence onset and phenotype. Sixty Italian OPA1 mutations carriers (fifty-two symptomatic), belonging to thirteen families, underwent neuro-ophthalmologic evaluation. Visual acuity (n=60) and Optical Coherence Tomography (OCT) (n=12) were compared in missense mutations (OPA-M) versus haploinsufficiency-inducing mutations (OPA-H) and correlated with age. Presence of plus phenotypes was investigated. We found four known mutations, the most common being missense c.1034G>A, and a new missense mutation, c1193A>C, the latter in a 54-yrs old female with late-onset phenotype. Visual acuity, colour sensitivity, and optic disc atrophy were sensitive indicators of disease. OCT RNFL thickness was reduced in OPA1 compared to controls. OPA-M showed worst visual acuity than OPA-H, but not more frequent plus-phenotype, observed only in four OPA-H patients. In both groups, visual acuity worsened with age. Our data confirm worst vision in OPA-M, but not increased plus-phenotype. Since most patients belonged to nine families from south-eastern Sicily (a famous region for the cult of St. Lucy, patron of the blinds) local genetic and environmental factors might have accounted for the low occurrence of plus-phenotypes.
Assuntos
GTP Fosfo-Hidrolases/genética , Mutação de Sentido Incorreto , Atrofia Óptica Autossômica Dominante/diagnóstico por imagem , Atrofia Óptica Autossômica Dominante/genética , Tomografia de Coerência Óptica , Adulto , Fatores Etários , Estudos de Coortes , Família , Feminino , Estudos de Associação Genética , Heterozigoto , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Atrofia Óptica Autossômica Dominante/fisiopatologia , Fenótipo , Acuidade Visual , Adulto JovemRESUMO
Optic atrophy type 1 (OPA1) gene mutation causes autosomal dominant optic atrophy (ADOA, MIM #165500). Prevalence of ADOA ranges from 1:50,000 in most populations to 1:12,000 in Denmark. Seventy members of nine families were analysed for the presence of OPA1 gene mutations by polymerase chain reaction (PCR) and direct sequencing. We identified three OPA1 gene mutations in 48 patients with variable signs of optic atrophy. Two mutations, c.784-21_784-22insAluYb8 and c.876_878delTGT, were found in two different families. The third mutation, c.869G>A, was found in 28 patients from seven families. The haplotype analysis data suggested that the c.869G>A mutation is a founder mutation. Our main result suggests a higher ADOA prevalence in south-eastern Sicily than previously found in Denmark. This is because of not only the founder effect but also to the presence of three different mutations in the geographical area of the study. Our hypothesis is that a combination of social pressure because of blindness and migration factors is involved. In fact, in Siracusa, a provincial capital in south-eastern Sicily, St. Lucy, the patron saint of the blind was born and died.
Assuntos
GTP Fosfo-Hidrolases/genética , Frequência do Gene , Mutação , Atrofia Óptica Autossômica Dominante/epidemiologia , Atrofia Óptica Autossômica Dominante/genética , Adolescente , Adulto , Idoso , Criança , Pré-Escolar , Haplótipos , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Linhagem , Prevalência , SicíliaRESUMO
BACKGROUND AND PURPOSE: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive disease, because of sterol 27-hydroxylase deficiency. Clinical manifestations of CTX are tendon xanthomas, juvenile cataracts, osteoporosis, diarrhoea and multiple progressive neurological dysfunctions. More than 300 patients with CTX have been reported to date worldwide and about fifty different mutations identified in CYP27A1 gene. This study describes the clinical and laboratory findings of seven new patients. METHODS: We report the molecular and clinical characterization of seven new Italian patients with CTX carrying four novel mutations. RESULTS: We identified four novel mutations located in different exons, in particular in the region of exons 2-5 of the CYP27A1 gene. Phenotypical expression did not differ from classical CTX presentation except for absence of tendon xanthomas in two patients.
Assuntos
Colestanotriol 26-Mono-Oxigenase/deficiência , Colestanotriol 26-Mono-Oxigenase/genética , Predisposição Genética para Doença/genética , Mutação/genética , Xantomatose Cerebrotendinosa/enzimologia , Xantomatose Cerebrotendinosa/genética , Adolescente , Adulto , Feminino , Humanos , Itália , Masculino , Xantomatose Cerebrotendinosa/diagnóstico , Adulto JovemRESUMO
We sequenced all genes of mitochondrial tRNAs of a patient with chronic progressive external ophthalmoplegia with 5% ragged red fibres and 15% COX-negative fibres but without macrorearrangements of mitochondrial DNA (mtDNA). Direct sequencing showed a novel heteroplasmic G>A substitution in position 12316 of tRNA(Leu(CUN)) gene. This change destroys a highly conserved G-C base coupling in tRNA TpsiC branch. By RFLP analysis we could demonstrate different degrees of heteroplasmy in different patient's tissues. This alteration, absent in a population of 110 patients with different encephalomyopathies, can be considered pathogenic: it is the tenth tRNA(Leu(CUN)) pathogenic mutation described up to date.
Assuntos
DNA Mitocondrial/genética , Mutação , Oftalmoplegia Externa Progressiva Crônica/genética , RNA de Transferência de Leucina/genética , Análise Mutacional de DNA , Feminino , Humanos , Pessoa de Meia-Idade , Músculo Esquelético/patologia , Oftalmoplegia Externa Progressiva Crônica/patologiaAssuntos
Colestanotriol 26-Mono-Oxigenase/genética , Predisposição Genética para Doença/genética , Mutação/genética , Xantomatose Cerebrotendinosa/diagnóstico , Xantomatose Cerebrotendinosa/genética , Adolescente , Argentina , Encéfalo/enzimologia , Encéfalo/patologia , Encéfalo/fisiopatologia , Colestanol/sangue , Colesterol/metabolismo , Análise Mutacional de DNA , Feminino , Marcadores Genéticos/genética , Testes Genéticos , Genótipo , Humanos , Deficiência Intelectual/enzimologia , Deficiência Intelectual/genética , Deficiência Intelectual/fisiopatologia , Imageamento por Ressonância Magnética , Masculino , Mitocôndrias/enzimologia , Mitocôndrias/genética , Tremor/enzimologia , Tremor/genética , Tremor/fisiopatologia , Xantomatose Cerebrotendinosa/fisiopatologiaRESUMO
The authors describe the principal forms of genetic leucodystrophies with unknown metabolic pathogenesis, indicating their main clinical signs and the new findings concerning the molecular genetic that are useful for the laboratory confirmation of the clinical suspicion.
Assuntos
Leucoencefalopatia Multifocal Progressiva/classificação , Leucoencefalopatia Multifocal Progressiva/genética , Doenças Desmielinizantes/etiologia , Doenças Desmielinizantes/patologia , Diagnóstico Diferencial , Humanos , Leucoencefalopatia Multifocal Progressiva/diagnóstico , Leucoencefalopatia Multifocal Progressiva/etiologia , Leucoencefalopatia Multifocal Progressiva/patologiaRESUMO
Midbrain dopaminergic (DA) neurons subserve complex and varied neural functions in vertebrate CNS. Their progenitors give rise to DA neurons by the action of two extracellular inducers, Sonic Hedgehog and FGF8. After this first commitment, the function of selectively activated transcription factors, like the orphan steroid nuclear receptor Nurr1, is required for DA final determination. Subsequently, DA function is selectively modulated by specific interaction with the developing striatal target tissue. Committed and determined DA neurons express the key genes involved in DA neurotransmission at different times in development. Synthesis and intracellular accumulation of DA is achieved shortly after expression of Nurr1, while high affinity uptake, responsible for ending the neurotransmission, takes place after a few days. Cell contacts between the presynaptic DA neurons and target striatal neurons are apparently necessary for the fine modulation of DA function, in vivo and in vitro.